Under construction – not a live service
Sign in
Taking people in CanadaPhase 3

Evaluating Oral Peri-operative Acetylsalicylic Acid in Subjects Undergoing Endovascular Coiling-only of Unruptured Brain Aneurysms

Key facts

Where
Calgary, Edmonton, Halifax, Hamilton, Montreal, Saskatoon, and Toronto, CanadaSee the 8 sites
Phase
Phase 3

Where in Canada

  • Foothills Medical CenterCalgary, CanadaContact: Dr Alim Mitha, MD FRCSCTaking people
  • U of AlbertaEdmonton, CanadaContact: Cian O'Kelly, MD FRCSCTaking people
  • Dalhousie UniversityHalifax, CanadaContact: Adrienne Weeks, MD, PhD, FRCSCTaking people
  • McMaster UniversityHamilton, CanadaContact: BRIAN VAN ADEL, MD, PhD, FRCPCTaking people
  • McGill UniversityMontreal, CanadaContact: Maria Cortes, MDTaking people
  • University of SaskatchewanSaskatoon, CanadaContact: Michael Kelly, MD, PhD, FRCSC, FACS, FAANSTaking people
  • Toronto St Michael's HospitalToronto, CanadaContact: Aditya Bharatha, MD FRCPCTaking people
  • Toronto Western HospitalToronto, CanadaContact: Ronit Agid, MD, FRCPCTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
University of Calgary
Trial code
NCT04192955
Record updated
2 September 2026
Original description
This trial is a is a prospective, randomized (1:1) placebo-controlled, clinical trial with blinded endpoint assessment of 440 participants with unruptured brain aneurysm planned for endovascular treatment using coiling-only approach (primary coiling or using balloon-assistance but not stenting) to test if oral acetylsalicylic acid (325 mg/ day for a total of 5 days) is superior placebo in preventing clinical and silent strokes. The primary outcome is a clinical or silent stroke at the time of discharge assessed by clinical examination and MRI brain. Participants will return to the clinic or be contacted by phone for the end of study procedures on Day 90 to collect functional outcome data.Read full original descriptionShow less

Evaluating Oral Peri-operative Acetylsalicylic Acid in Subjects Undergoing Endovascular Coiling-only of Unruptured Brain Aneurysms(EVOLVE): A Phase 3 Multicenter Randomized Study

This trial is a is a prospective, randomized (1:1) placebo-controlled, clinical trial with blinded endpoint assessment of 440 participants with unruptured brain aneurysm planned for endovascular treatment using coiling-only approach (primary coiling or using balloon-assistance but not stenting) to test if oral acetylsalicylic acid (325 mg/ day for a total of 5 days) is superior placebo in preventing clinical and silent strokes. The primary outcome is a clinical or silent stroke at the time of discharge assessed by clinical examination and MRI brain. Participants will return to the clinic or be contacted by phone for the end of study procedures on Day 90 to collect functional outcome data.

Inclusion: Unruptured intracranial aneurysm suitable for coiling-only (primary coiling or balloon-assisted) as a primary treatment; Functionally independent at baseline (modified Rankin scale <3); Informed consent and availability of the subject for the entire study period.

Exclusion: Planned complex aneurysm treatment including use of any device that requires post-operative antiplatelet therapy (stent-assisted coiling or flow-diverter device), or endovascular vessel sacrifice; Any ongoing ischemic symptoms such as transient ischemic attacks, minor strokes, or stroke-in-evolution within 2 weeks before randomization; Unable to take study drug orally for any reason; Prior enrollment in EVOLVE trial for another aneurysm; Participation in another clinical trial of an investigational drug, device or procedure if the subject received the trial drug, device or procedure in the preceding 30 days from the anticipated coiling date; Allergy or contraindication to ASA; Any other medical condition that the site investigator deems would put the subject at excessive risk by participation in the study (e.g. active bleeding, symptomatic peptic ulcer disease, liver or kidney failure, thrombocytopenia or coagulopathy) or an expected life expectancy less than one year, or that would result in an inability to collect radiological outcomes and clinical outcomes at 90 days; Dissecting or mycotic brain aneurysm; Subjects already taking single or dual antiplatelet, warfarin, or any of the non-Vitamin K antagonist oral anticoagulants; Subjects unable to undergo MRI imaging for any reason (e.g., severe claustrophobia or presence of metals); Pregnancy or breastfeeding.

ClinicalTrials.gov NCT04192955